

CSD/BSE&NSE/CC/2024-25 February 6, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064 Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

**Sub: Schedule of Conference Call for Investors** 

With reference to above subject, please find enclosed intimation regarding schedule of conference call for investors on Wednesday, February 12, 2025 at 06.30 p.m. IST to discuss the Un-audited Financial Results for the Q3 & 9M FY25, to be considered on February 12, 2025.

This is for your information and record.

Thanking You.

Yours faithfully, For Suven Pharmaceuticals Limited

#### Kundan Kumar Jha

Company Secretary, Compliance Officer and Head-Legal

Encl: as above

# Suven Pharmaceuticals Limited

**Registered Office:** # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India Tel: 91 22 61539999

**Corporate Office:** # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081 Telangana, India Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236



# Suven Pharmaceuticals Ltd to host Q3 & 9MFY25 Results Conference call on Wednesday, February 12, 2025 @ 6.30 pm

Suven Pharmaceuticals Ltd will conduct a conference call to discuss its Q3 & 9MFY25 results performance. The management team will be represented by Mr. Vivek Sharma (Executive Chairman), Dr. V Prasada Raju (Managing Director), Dr. Sudhir Kumar Singh (Chief Executive Officer), Mr. Himanshu Agarwal (Chief Financial Officer) & Cyndrella Carvalho (Head – IR).

The conference call will be initiated with a brief discussion after which the floor will be opened for Q&As. The financial results will be announced earlier on February 12, 2025.

In order to pre-register: Copy this URL in your browser:

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=2820130 &linkSecurityString=134300f00e

## Details of the conference call are as follows:

Timing	6.30 pm IST on Wednesday, February 12, 2025
Conference dial-in	
Primary number	+91 22 6280 1141/+91 22 7115 8042
Singapore Toll Free Number	800 101 2045
Hong Kong Toll Free Number	800 964 448
USA Toll Free Number	1 866 746 2133
UK Toll Free Number	0 808 101 1573

- ENDS -

### For further information please contact

Cyndrella Carvalho, (Head – Investor Relations)
Suven Pharmaceuticals Limited

Tel: +91 40 2354 9414

Email: <a href="mailto:cyndrella.carvalho@suvenpharm.com">cyndrella.carvalho@suvenpharm.com</a>

Gavin Desa / Rishab Barar

CDR India

Tel: +91 98206 37649 / 77770 35061

Email: gavin@cdr-india.com

rishab@cdr-india.com